Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Long-term outcomes in juvenile idiopathic arthritis: Eighteen Years of Follow-Up in the Population-Based Nordic Juvenile Idiopathic Arthritis Cohort

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Glerup, M, Rypdal, V, Arnstad, ED, Ekelund, M, Peltoniemi, S, Aalto, K, Rygg, M, Toftedal, P, Nielsen, S, Fasth, A, Berntson, L, Nordal, E, Herlin, T & Nordic Study Group of Pediatric Rheumatology (NoSPeR) 2020, 'Long-term outcomes in juvenile idiopathic arthritis: Eighteen Years of Follow-Up in the Population-Based Nordic Juvenile Idiopathic Arthritis Cohort', Arthritis Care & Research, bind 72, nr. 4, s. 507-516. https://doi.org/10.1002/acr.23853

APA

Glerup, M., Rypdal, V., Arnstad, E. D., Ekelund, M., Peltoniemi, S., Aalto, K., Rygg, M., Toftedal, P., Nielsen, S., Fasth, A., Berntson, L., Nordal, E., Herlin, T., & Nordic Study Group of Pediatric Rheumatology (NoSPeR) (2020). Long-term outcomes in juvenile idiopathic arthritis: Eighteen Years of Follow-Up in the Population-Based Nordic Juvenile Idiopathic Arthritis Cohort. Arthritis Care & Research, 72(4), 507-516. https://doi.org/10.1002/acr.23853

CBE

Glerup M, Rypdal V, Arnstad ED, Ekelund M, Peltoniemi S, Aalto K, Rygg M, Toftedal P, Nielsen S, Fasth A, Berntson L, Nordal E, Herlin T, Nordic Study Group of Pediatric Rheumatology (NoSPeR). 2020. Long-term outcomes in juvenile idiopathic arthritis: Eighteen Years of Follow-Up in the Population-Based Nordic Juvenile Idiopathic Arthritis Cohort. Arthritis Care & Research. 72(4):507-516. https://doi.org/10.1002/acr.23853

MLA

Vancouver

Author

Glerup, Mia ; Rypdal, Veronika ; Arnstad, Ellen Dalen ; Ekelund, Maria ; Peltoniemi, Suvi ; Aalto, Kristiina ; Rygg, Marite ; Toftedal, Peter ; Nielsen, Susan ; Fasth, Anders ; Berntson, Lillemor ; Nordal, Ellen ; Herlin, Troels ; Nordic Study Group of Pediatric Rheumatology (NoSPeR). / Long-term outcomes in juvenile idiopathic arthritis : Eighteen Years of Follow-Up in the Population-Based Nordic Juvenile Idiopathic Arthritis Cohort. I: Arthritis Care & Research. 2020 ; Bind 72, Nr. 4. s. 507-516.

Bibtex

@article{1ca6aa8c251e4069a7705e89c7c79f91,
title = "Long-term outcomes in juvenile idiopathic arthritis: Eighteen Years of Follow-Up in the Population-Based Nordic Juvenile Idiopathic Arthritis Cohort",
abstract = "OBJECTIVE: The present study was undertaken to assess the long-term course, remission rate, and disease burden in juvenile idiopathic arthritis (JIA) 18 years after disease onset in a population-based setting from the early biologic era.METHODS: A total of 510 consecutive cases of JIA with disease onset between 1997 and 2000 from defined geographic regions in Denmark, Norway, Sweden, and Finland were prospectively included in this 18-year cohort study. At the follow-up visit, patient-reported demographic and clinical data were collected.RESULTS: The study included 434 (85%) of the 510 eligible JIA participants. The mean ± SD age was 24.0 ± 4.4 years. The median juvenile arthritis disease activity score in 71 joints (JADAS-71) was 1.5 (interquartile range [IQR] 0-5), with the enthesitis-related arthritis (ERA) category of JIA having the highest median score (4.5 [IQR 1.5-8.5], P = 0.003). In this cohort, 46% of patients still had active disease, and 66 (15%) were treated with synthetic disease-modifying antirheumatic drugs and 84 (19%) with biologics. Inactive disease indicated by a JADAS-71 score of <1 was seen in 48% of participants. Clinical remission off medication (CR) was documented in 33% of the participants with high variability among the JIA categories. CR was most often seen in persistent oligoarticular and systemic arthritis and least often in ERA (P < 0.001).CONCLUSION: A substantial proportion of the JIA cohort did not achieve CR despite new treatment options during the study period. The ERA category showed the worst outcomes, and in general there is still a high burden of disease in adulthood for JIA.",
author = "Mia Glerup and Veronika Rypdal and Arnstad, {Ellen Dalen} and Maria Ekelund and Suvi Peltoniemi and Kristiina Aalto and Marite Rygg and Peter Toftedal and Susan Nielsen and Anders Fasth and Lillemor Berntson and Ellen Nordal and Troels Herlin and {Nordic Study Group of Pediatric Rheumatology (NoSPeR)}",
note = "{\textcopyright} 2019, American College of Rheumatology.",
year = "2020",
month = apr,
doi = "10.1002/acr.23853",
language = "English",
volume = "72",
pages = "507--516",
journal = "Arthritis Care & Research",
issn = "2151-464X",
publisher = "JohnWiley & Sons, Inc",
number = "4",

}

RIS

TY - JOUR

T1 - Long-term outcomes in juvenile idiopathic arthritis

T2 - Eighteen Years of Follow-Up in the Population-Based Nordic Juvenile Idiopathic Arthritis Cohort

AU - Glerup, Mia

AU - Rypdal, Veronika

AU - Arnstad, Ellen Dalen

AU - Ekelund, Maria

AU - Peltoniemi, Suvi

AU - Aalto, Kristiina

AU - Rygg, Marite

AU - Toftedal, Peter

AU - Nielsen, Susan

AU - Fasth, Anders

AU - Berntson, Lillemor

AU - Nordal, Ellen

AU - Herlin, Troels

AU - Nordic Study Group of Pediatric Rheumatology (NoSPeR)

N1 - © 2019, American College of Rheumatology.

PY - 2020/4

Y1 - 2020/4

N2 - OBJECTIVE: The present study was undertaken to assess the long-term course, remission rate, and disease burden in juvenile idiopathic arthritis (JIA) 18 years after disease onset in a population-based setting from the early biologic era.METHODS: A total of 510 consecutive cases of JIA with disease onset between 1997 and 2000 from defined geographic regions in Denmark, Norway, Sweden, and Finland were prospectively included in this 18-year cohort study. At the follow-up visit, patient-reported demographic and clinical data were collected.RESULTS: The study included 434 (85%) of the 510 eligible JIA participants. The mean ± SD age was 24.0 ± 4.4 years. The median juvenile arthritis disease activity score in 71 joints (JADAS-71) was 1.5 (interquartile range [IQR] 0-5), with the enthesitis-related arthritis (ERA) category of JIA having the highest median score (4.5 [IQR 1.5-8.5], P = 0.003). In this cohort, 46% of patients still had active disease, and 66 (15%) were treated with synthetic disease-modifying antirheumatic drugs and 84 (19%) with biologics. Inactive disease indicated by a JADAS-71 score of <1 was seen in 48% of participants. Clinical remission off medication (CR) was documented in 33% of the participants with high variability among the JIA categories. CR was most often seen in persistent oligoarticular and systemic arthritis and least often in ERA (P < 0.001).CONCLUSION: A substantial proportion of the JIA cohort did not achieve CR despite new treatment options during the study period. The ERA category showed the worst outcomes, and in general there is still a high burden of disease in adulthood for JIA.

AB - OBJECTIVE: The present study was undertaken to assess the long-term course, remission rate, and disease burden in juvenile idiopathic arthritis (JIA) 18 years after disease onset in a population-based setting from the early biologic era.METHODS: A total of 510 consecutive cases of JIA with disease onset between 1997 and 2000 from defined geographic regions in Denmark, Norway, Sweden, and Finland were prospectively included in this 18-year cohort study. At the follow-up visit, patient-reported demographic and clinical data were collected.RESULTS: The study included 434 (85%) of the 510 eligible JIA participants. The mean ± SD age was 24.0 ± 4.4 years. The median juvenile arthritis disease activity score in 71 joints (JADAS-71) was 1.5 (interquartile range [IQR] 0-5), with the enthesitis-related arthritis (ERA) category of JIA having the highest median score (4.5 [IQR 1.5-8.5], P = 0.003). In this cohort, 46% of patients still had active disease, and 66 (15%) were treated with synthetic disease-modifying antirheumatic drugs and 84 (19%) with biologics. Inactive disease indicated by a JADAS-71 score of <1 was seen in 48% of participants. Clinical remission off medication (CR) was documented in 33% of the participants with high variability among the JIA categories. CR was most often seen in persistent oligoarticular and systemic arthritis and least often in ERA (P < 0.001).CONCLUSION: A substantial proportion of the JIA cohort did not achieve CR despite new treatment options during the study period. The ERA category showed the worst outcomes, and in general there is still a high burden of disease in adulthood for JIA.

U2 - 10.1002/acr.23853

DO - 10.1002/acr.23853

M3 - Journal article

C2 - 30762291

VL - 72

SP - 507

EP - 516

JO - Arthritis Care & Research

JF - Arthritis Care & Research

SN - 2151-464X

IS - 4

ER -

ID: 58928315